Leiomyosarcoma - 29 Studies Found
| Completed |
: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus :
|
| Completed |
: Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas :
: 2011-08-29 : Drug: Gemcitabine + Trabectedin Combination therapy of gemcitabine and trabectedin |
| Completed |
: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer :
: 2003-05-16 :
|
| Completed |
: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working : Locally Advanced Uterine Corpus Leiomyosarcoma : 2025-09-05 : Undergo collection of blood samples |
| Completed |
: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma : Leiomyosarcoma : 2025-09-05 : Intravenous Infusion |
| Completed |
: Localized Leiomyosarcoma Biomarker Protocol : Leiomyosarcoma : 2025-09-05 : Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change |
| COMPLETED |
: Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma : Leiomyosarcoma : 2025-09-05 : Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2) |
| COMPLETED |
: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma : Leiomyosarcoma : 2025-09-05 : Rucaparib at 600 mg, orally, twice daily, continuously for 28 days. |
| COMPLETED |
: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma : Leiomyosarcoma : 2025-09-05 : Rucaparib at 600 mg, orally, twice daily, continuously for 28 days. |